Literature DB >> 2314388

Characterization of the binding of [3H]Ro 41-1049 to the active site of human monoamine oxidase-A.

A M Cesura1, M Bös, M D Galva, R Imhof, M Da Prada.   

Abstract

The novel reversible and selective inhibitor of monoamine oxidase-A (MAO-A) Ro 41-1049 [N-(2-aminoethyl)-5-(m-fluorophenyl)-4-thiazole carboxamide HCl] shows inhibition characteristics similar to those of the structurally related reversible MAO-B inhibitors Ro 16-6491 and Ro 19-6327. In the present study, tritiated Ro 41-1049 was used as a high affinity ligand to study the binding characteristics of this inhibitor to MAO-A and its interactions with the enzyme. An homogeneous population of high affinity binding sites for [3H]Ro 41-1049 was found in membrane preparations from human frontal cortex and placenta (Kd = 16.5 +/- 1.4 and 64.4 +/- 19.2 nM, respectively). In frontal cortex the Bmax value for [3H]Ro 41-1049 (2.6 +/- 0.4 pmol/mg of protein) was about one third of the Bmax calculated for the MAO-B-selective ligand [3H]Ro 16-6491. The density of [3H]Ro 41-1049 binding sites in human placenta varied greatly in the different tissue samples investigated, showing an average Bmax of 101.7 +/- 36.5 pmol/mg of protein. Apparent binding equilibrium was reached after 1 hr of incubation at 37 degrees. At this temperature the binding was reversible, with a dissociation t 1/2 of about 35 min. At lower temperatures the radioactivity dissociation was much slower. Among the various drugs tested, only inhibitors of MAO-A were able to effectively prevent [3H]Ro 41-1049 specific binding. As previously reported for the MAO-B ligands [3H]Ro 16-6491 and [3H]Ro 19-6327, the analysis of the membrane-bound radioactivity showed that [3H]Ro 41-1049 was entirely recovered in the form of its aldehyde derivative, indicating that Ro 41-1049 was deaminated by MAO-A. The existence of a Ro 41-1049 adduct reversibly bound to the enzyme active site might explain the inhibition mechanism of this compound. The exposure of the radioligand-enzyme complex to NaBH3CN at pH 4.5 caused the irreversible covalent incorporation of about 70% of the specifically bound radioactivity into a 60-kDa polypeptide. This incorporation was dependent on the pH and on the amount of NaBH3CN added. The presence of MAO-A- but not MAO-B-selective inhibitors prevented the covalent incorporation of [3H]Ro 41-1049. The present results indicate that [3H]Ro 41-1049 is incorporated into a subunit of MAO-A, in the presence of NaBH3CN, and modifies a protein domain that is essential for the enzyme activity.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2314388

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  10 in total

1.  Forebrain-specific expression of monoamine oxidase A reduces neurotransmitter levels, restores the brain structure, and rescues aggressive behavior in monoamine oxidase A-deficient mice.

Authors:  Kevin Chen; Olivier Cases; Igor Rebrin; Weihua Wu; Timothy K Gallaher; Isabelle Seif; Jean Chen Shih
Journal:  J Biol Chem       Date:  2006-11-07       Impact factor: 5.157

2.  Effects of the antidepressant pirlindole and its dehydro-derivative on the activity of monoamine oxidase-A and on GABAA receptors.

Authors:  A E Medvedev; V I Shvedov; T M Chulkova; O A Fedotova; E Saederup; R F Squires
Journal:  Neurochem Res       Date:  1996-12       Impact factor: 3.996

3.  Conventional Receptor Radioligand Binding Techniques Applied to the Study of Monoamine Oxidase.

Authors:  Andrew Holt
Journal:  Methods Mol Biol       Date:  2023

Review 4.  Roles of selected non-P450 human oxidoreductase enzymes in protective and toxic effects of chemicals: review and compilation of reactions.

Authors:  Slobodan P Rendić; Rachel D Crouch; F Peter Guengerich
Journal:  Arch Toxicol       Date:  2022-06-01       Impact factor: 6.168

5.  Mode of action and characteristics of monoamine oxidase-A inhibition by moclobemide.

Authors:  A M Cesura; R Kettler; R Imhof; M Da Prada
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

6.  Comparison of the in vitro binding characteristics of the beta-carbolines harman and norharman in rat brain and liver and in bovine adrenal medulla.

Authors:  T May; A Greube; S Strauss; D Heineke; J Lehmann; H Rommelspacher
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-03       Impact factor: 3.000

7.  In vivo quantification of monoamine oxidase A in baboon brain: a PET study using [(11)C]befloxatone and the multi-injection approach.

Authors:  Michel Bottlaender; Héric Valette; Jacques Delforge; Wadad Saba; Ilonka Guenther; Olivier Curet; Pascal George; Frédéric Dollé; Marie-Claude Grégoire
Journal:  J Cereb Blood Flow Metab       Date:  2009-11-18       Impact factor: 6.200

8.  Chronic treatment with the monoamine oxidase inhibitors clorgyline and pargyline down-regulates non-adrenoceptor [3H]-idazoxan binding sites in the rat brain.

Authors:  G Olmos; A M Gabilondo; A Miralles; P V Escriba; J A García-Sevilla
Journal:  Br J Pharmacol       Date:  1993-03       Impact factor: 8.739

9.  20 ans après: a second mutation in MAOA identified by targeted high-throughput sequencing in a family with altered behavior and cognition.

Authors:  Amélie Piton; Hélène Poquet; Claire Redin; Alice Masurel; Julia Lauer; Jean Muller; Julien Thevenon; Yvan Herenger; Sophie Chancenotte; Marlène Bonnet; Jean-Michel Pinoit; Frédéric Huet; Christel Thauvin-Robinet; Anne-Sophie Jaeger; Stéphanie Le Gras; Bernard Jost; Bénédicte Gérard; Katell Peoc'h; Jean-Marie Launay; Laurence Faivre; Jean-Louis Mandel
Journal:  Eur J Hum Genet       Date:  2013-10-30       Impact factor: 4.246

10.  Analgesic efficacy of CR4056, a novel imidazoline-2 receptor ligand, in rat models of inflammatory and neuropathic pain.

Authors:  Flora Ferrari; Simonetta Fiorentino; Laura Mennuni; Paolo Garofalo; Ornella Letari; Stefano Mandelli; Antonio Giordani; Marco Lanza; Gianfranco Caselli
Journal:  J Pain Res       Date:  2011-04-18       Impact factor: 3.133

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.